Evaluation of Adverse Events, Pharmacokinetics, and Disease Activity of Intravenous ABBV-291 in Adults With Non-Hodgkin's Lymphoma

The primary objective of this study is to evaluate **adverse events** and changes in **disease activity** in adult participants with **Non-Hodgkin's Lymphoma** following intravenous infusion of ABBV-291. This is clinically relevant as it aims to assess the safety profile and therapeutic impact of ABBV-291, which could inform treatment strategies and improve patient outcomes in this population.

The clinical trial involves a total of **101 participants** diagnosed with **Non-Hodgkin's Lymphoma**. The study population includes both male and female subjects, with an age range that spans from adults to the elderly. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, and there are no specific lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the principal inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **adverse events**, changes in disease activity, and pharmacokinetics of intravenously infused ABBV-291 in adult participants diagnosed with **Non-Hodgkin's Lymphoma**. This study is structured as a Phase 1 trial, which is typically focused on assessing safety and dosage. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and reliable data collection. The estimated duration of the trial spans from the recruitment start date on August 18, 2025, to the anticipated end date on June 9, 2032.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve comprehensive assessments to confirm the diagnosis and evaluate baseline health status. Following successful screening, participants will be randomized into treatment groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment, record any adverse events, and collect pharmacokinetic data. These visits are crucial for ensuring participant safety and the integrity of the trial data.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the overall impact of the treatment. The expected length of participant involvement will vary depending on individual response and the specific protocol requirements. Conditions that may lead to early termination from the study include significant adverse events, withdrawal of consent, or any other protocol-defined criteria that compromise participant safety or data integrity.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the source data. Information such as the parameters or endpoints used to evaluate efficacy, the methods and schedule for measuring, collecting, and analyzing these efficacy parameters, and any tools or instruments involved in efficacy assessments are not available. The trial is identified as a Phase 1 study, with an estimated recruitment start date of August 18, 2025, and an estimated end date of June 9, 2032. Further details on efficacy assessment are not specified.